You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020139068
Dec 20204406
Jan 20213805
Feb 202142016
Mar 202182012
Apr 202180021
May 202132012
Jun 20210024
Jul 2021006
Aug 20210023
Sep 20210014
Oct 202196034
Nov 202188023
Dec 202168019
Jan 202272015
Feb 202264014
Mar 20227809
Apr 202210408
May 20226606
Jun 20227007
Jul 20226007
Aug 20225009
Sep 20225805
Oct 20224401
Nov 20224806
Dec 20223803
Jan 20232600
Feb 20232203
Mar 20232409
Apr 202324014
May 20232403
Jun 20232402
Jul 20231806
Aug 20232004
Sep 20231603
Oct 20231806
Nov 20232401
Dec 20233601
Jan 20242401
Feb 20242601
Mar 20241804
Apr 20242805
May 20242002
Jun 20241806
Jul 20242804
Aug 20241000
Sep 20243603
Total19450451